IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXXNYSE / NASDAQHealthcareLarge cap

$676.21-$13.44 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$44.5B
P/E
42.0x
EV / EBITDA
30.1x
Revenue
$4.3B
Net margin
24.6%
ROCE
61.8%

-1.9% over the last year

IDEXX Laboratories, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+21.2%
3M
+23.9%
6M
+22.2%
1Y
-1.9%
5Y
+4.5%

52-week range

Day change -$13.44 (-1.9%) from $690 to $676 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IDXX, bought on each weekday since 2021.

News & filings

What IDEXX Laboratories filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 31.6% against a peer median of 13.6%.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read moreShow less

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Sector
Healthcare
Shares outstanding
80.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$44.5B
P/E
42.0x
P/B
27.7x
EV / EBITDA
30.1x
EV / Sales
10.5x
P/S
10.4x
52-week high
$766.68
52-week low
$504.70

Profitability

Operating margin
31.6%
Net margin
24.6%
EBITDA margin
35.0%
ROE
66.0%
ROCE
61.8%
ROA
31.6%
Asset turnover
1.28

Growth

Revenue
$4.3B
Revenue growth, 1Y
10.4%
Revenue CAGR, 3Y
8.5%
Net profit growth, 1Y
19.3%
Free cash flow
$1.0B

Solvency

Current ratio
1.23
Debt / Equity
0.61
Debt / Assets
0.29
CFO / Net profit
1.12
Cash / Market cap
0.4%

Where the revenue went

Of every $100 of FY2025 revenue, $25 was left as net income.

IDEXX Laboratories, Inc. income statement flow, FY2025
IDEXX Laboratories, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.6B
RevenueGross profit$2.7B
Gross profitResearch and development$251.2M
Gross profitSelling, general and administrative$1.0B
Gross profitOther operating expenses$0.00
Gross profitOperating income$1.4B
Operating incomePretax income$1.3B
Operating incomeInterest and other expense$35.8M
Pretax incomeTax and other$264.7M
Pretax incomeNet income$1.1B

Revenue and net profit

Revenue grew 10.4% in FY2025; net profit is the dashed line.

IDEXX Laboratories, Inc. revenue and net profit by fiscal year
IDEXX Laboratories, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.4B$679.1M
FY2023$3.7B$845.0M
FY2024$3.9B$887.9M
FY2025$4.3B$1.1B

Cash flows

FY2025: $1.2B from operations, $1.0B free after investment (dashed).

IDEXX Laboratories, Inc. operating and free cash flow by fiscal year
IDEXX Laboratories, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$543.0M$384.1M
FY2023$906.5M$772.9M
FY2024$929.0M$798.1M
FY2025$1.2B$1.0B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.3B+10.4%1Y
EBITDA
$1.5B+18.7%1Y
Net profit
$1.1B+19.3%1Y
Cash from operations
$1.2B+27.2%1Y
Free cash flow
$1.0B+30.8%1Y
Revenue CAGR, 3Y
8.5%
Net profit CAGR, 3Y
16.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.3B$1.5B$1.1B$1.0B66.0%+10.4%+19.3%

Monthly returns

Month-by-month returns of IDXX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.4B
Liabilities$1.7B
Equity$1.6B
Paid-in capital$1.8B
Retained earnings$6.4B
Treasury stock$6.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IDXX highlighted.

P/E against peers

IDXX trades at 42.0x earnings against a peer median of 34.6x (a 22% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
IDEXX Laboratories, Inc.IDXXthis companyP/E ↑ premium$44.5B42.0x27.7x66.0%30.1x
Cencora, Inc.COR$52.6B33.8x34.9x103.1%14.9x
Edwards Lifesciences CorporationEW$50.4B46.9x4.9x10.4%33.2x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Peer median—34.6x5.3x14.9%22.1x

Year-to-date ROI

IDXX since 1 January, against earlier years.

Historical volatility

IDXX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

IDEXX Laboratories, Inc. operating margin by fiscal year
IDEXX Laboratories, Inc. operating margin by fiscal year
DateOperating margin
FY202226.7%
FY202330.0%
FY202429.0%
FY202531.6%
LineFY2025
Cost of revenueCost Of Revenue$1.6B
Gross profitGross Profit$2.7B
Operating expensesOperating Expense$1.3B
Research and developmentResearch And Development$251.2M
Total expensesTotal Expenses$2.9B
Pretax incomePretax Income$1.3B

Learn while you research

Academy chapters picked for IDEXX Laboratories, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 42.0, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →